Business Wire

MA-EVALUATE

4.6.2019 14:02:06 CEST | Business Wire | Press release

Share
Innovation and Unmet Need Drive Prescription Drug Sales to $1.18tr by 2024: New Report from Evaluate Ltd

The $1.18tr forecast for the 2024 global prescription drug market reflects the role new technologies will play in addressing unmet medical needs, as strong expectations for immuno-oncology products and emerging cell and gene therapies drive growth. In 2018, new molecule approvals from the FDA reached their highest level in over a decade, and the projected CAGR of 6.9% from 2019-2024 significantly outpaces the 2.3% CAGR seen from 2010-2018.

Growth Drivers:

  • 2018 saw 62 FDA approvals for novel drugs, an increase over the 55 approvals in 2017
  • Oncology therapies to reach $237bn in 2024, with a CAGR of 11.4%
  • Orphan Drugs will contribute an additional $109bn in sales in 2024, compared to 2018

However, as more new technologies reach the market, drug pricing pressure may continue to intensify and dampen the overall sales outlook. R&D spending is also forecast to grow more slowly from 2019-2024 than in prior years, and decrease as a proportion of overall sales – a sign of either increasing R&D efficiency, or of companies focusing on smaller indications with lower clinical development costs.

Growth Brakes:

  • $198bn in sales are at risk between 2019 and 2024, due to patent expirations
  • Anti-rheumatics sales decline as Humira, Enbrel and Remicade face competition
  • R&D as a proportion of prescription sales is forecast to decline from 21.6% in 2018 to 18% in 2024

“Scientific advancements and health technologies are converging to deliver new options for patients, while challenging traditional drug development and commercialisation models,” said report author Ryan Waters. “The question is, which companies are best poised to take advantage of the evolving pharmaceutical market?”

Top Performers:

  • Pfizer will be the leading prescription drug company in 2024, with projected sales of $51.2bn
  • Keytruda is forecast to be the top selling drug in 2024, as Humira slips in the face of biosimilars
  • Johnson & Johnson overtakes Roche to be the biggest spender on pharmaceutical R&D in 2024

Download your complimentary copy of the “EvaluatePharma® World Preview 2019, Outlook to 2024” at https://www.evaluate.com/thought-leadership/pharma/evaluatepharma-world-preview-2019-outlook-2024 , or visit us at Booth #2243 at the BIO International Convention, June 3-6, in Philadelphia, PA.

About Evaluate Ltd.

Evaluate provides trusted commercial intelligence for the pharmaceutical and medical device industries. Our EvaluatePharma® and EvaluatePharma Vision online subscription services provide a seamless view of the past, present and future of the global pharmaceutical market in a single, standardised platform.

Vantage – our award-winning, independent editorial team – provides thought-provoking news and insights into the current and future developments in the industry.

Evaluate has been a partner to industry-leading organisations for over 20 years. For more information on how we give our clients the time and understanding to drive better decisions, visit www.evaluate.com .

Follow us on Twitter: @EvaluatePharma, @Vantageanalysis

Contact:

Media Contact: Evaluate and Vantage Jennifer Dinkel +1 617-936-7783 jennifer.dinkel@evaluate.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OLX Launches Agentic AI Products to Transform Property Search and Car Sales at CLAIM AI in Lisbon25.2.2026 15:33:00 CET | Press release

OLX launches CompassGPT and AutoIQ, making OLX the leading verticalised platform scaling Agentic AI across the entire value chain - supporting millions of buyers while simultaneously empowering professional customers. The Agentic Products were unveiled at CLAIM AI in Lisbon, OLX’s premier flagship event, bringing together industry leaders to showcase practical, powerful AI innovation OLX’s leading investments and application of proprietary AI deliver faster, smarter, and more user-centric marketplace experiences, with more than 75 AI use cases already in the market, including 10 agentic AI use cases launched in H126 OLX Group, the largest and fastest growing platform for vertical transactions in Europe and South Africa, today unveiled two new Agentic AI-powered products at CLAIM AI, its invite-only Lisbon conference for marketplace innovators. Launching in key OLX markets, CompassGPT introduces a conversational assistant to real estate search, while AutoIQ provides dealers with automot

KleanNara Partners with Rimini Street to Accelerate Digital Transformation25.2.2026 15:00:00 CET | Press release

South Korea’s leading paper manufacturer cuts SAP ECC 6 and Oracle Database maintenance costs with Rimini Support™, freeing up funds and team focus for AI-driven innovation and growth Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™, and the leading third-party support provider for Oracle, SAP and VMware software, today announced KleanNara has selected Rimini Street to provide support for its SAP ECC 6 and Oracle Database systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225123422/en/ KleanNara Partners with Rimini Street to Accelerate Digital Transformation Founded in 1966, KleanNara is one of South Korea’s leading manufacturers of paper and hygiene products. Holding a 25% share of the white cardboard market, the company is known for its commitment to quality, sustainability and innovation, and continues to expand globally with a focus on ESG-driven, eco-friendly products. Breaki

Axinn Adds Three Seasoned Antitrust Litigators, Reinforcing Trial Bench and West Coast Presence25.2.2026 15:00:00 CET | Press release

Hires Position Firm to Meet Rising Client Demand as Antitrust Enforcement Intensifies Axinn, Veltrop & Harkrider LLP announced today that Daniel Matheson, Katrina Rouse, and Jimmy Moore have joined its Antitrust practice as partners. Matheson arrives from the Federal Trade Commission (FTC), while Rouse and Moore join from the U.S. Department of Justice (DOJ) Antitrust Division. Rouse will join Axinn’s San Francisco office; Matheson and Moore will join the firm’s Washington, DC office. The additions strengthen Axinn's trial bench and West Coast practice as the firm continues to attract top antitrust talent. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225403123/en/ Daniel Matheson (Left), Katrina Rouse (Center), and Jimmy Moore (Right) have joined Axinn, Veltrop & Harkrider's LLP Antitrust practice as partners. “Axinn continues to invest in top-tier talent and trial capabilities as we deepen our commitment to clients and

Stonebranch Unveils Latest Release of Universal Data Mover Gateway (UDMG), Advancing Orchestrated B2B MFT25.2.2026 15:00:00 CET | Press release

Secure, enterprise-grade B2B managed file transfer meets orchestration to automate full processes once files are sent or received Stonebranch, a leading provider of service orchestration and automation solutions, today announced the latest release of its Universal Data Mover Gateway (UDMG) — an enterprise-grade managed file transfer (MFT) solution purpose-built for secure, orchestrated B2B data exchange across hybrid landscapes. “In today’s enterprises, file transfer is not a standalone task. It’s the backbone of data pipelines, analytics, and critical business processes,” said Giuseppe Damiani, CEO of Stonebranch. “By orchestrating MFT alongside workload and infrastructure automation, Stonebranch turns file movement into a governed, observable, SLA-driven part of end-to-end enterprise workflows.” Secure, Modern B2B Managed File Transfer UDMG is designed specifically for external B2B data exchanges — where stringent security, regulatory compliance, SLA reliability, and diverse partner

Klarna Reaches 55 Million Monthly App Users as Usage Surges 53% Year Over Year25.2.2026 14:00:00 CET | Press release

Every day 9 million users use Klarna’s app to help them bank and pay Klarna, the global digital bank and flexible payments provider, is seeing a sharp rise in both monthly and daily app usage, as more consumers use the global digital bank’s services as part of their everyday money management. The Klarna app now reaches more than 55 million monthly active users globally, with 9 million people using the app on a daily basis. Daily engagement has increased by approximately 53% compared with last year, highlighting increasingly frequent use of Klarna’s banking, spending and shopping services. Sebastian Siemiatkowski, CEO and co-founder of Klarna: “When people use Klarna every day, it shows we’re delivering on our vision of becoming the global digital bank for the next generation. Consumers are using the app to stay on top of their spending and manage their money, which is exactly how we see Klarna evolving into an everyday money management app people rely on in daily life.” The massive app

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye